Glut1 Deficiency Syndrome
8
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS
Baby Detect : Genomic Newborn Screening
The Glucose Transporter Type I Deficiency (G1D) Registry
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
Sodium Lactate Infusion in GLUT1DS Patients
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Post Study Continuation of C7 for G1D
Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)